The evaluation of the neutrophil–lymphocyte ratio (NLR) or platelet–lymphocyte ratio (PLR) in the HER2-positive breast cancer subgroup did not identify a statistically significant correlation with the clinical outcomes [21]. Here, ERBB2 is linked to breast carcinoma.